Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
To do IP due diligence for investment decisions
— Investment manager, South Korea
To check for drug patent status in MENA
— Pharmaceutical manufacturer, USA
To get information on pharmaceutical patents
— Business development, China
For drug patent information on drugs not available in Asia
— Pharmaceutical distribution, Singapore
To find information on expiration dates of patents in the Netherlands
— Hospital pharmacist, Netherlands
Generated: May 24, 2017
What are the generic drug sources for sirolimus and what is the scope of sirolimus freedom to operate?
Sirolimus is the generic ingredient in two branded drugs marketed by Pf Prism Cv, Zydus Pharms Usa Inc, and Dr Reddys Labs Ltd, and is included in four NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.| Tradenames: | 2 |
| Patents: | 2 |
| Applicants: | 3 |
| NDAs: | 4 |
| Drug Master File Entries: see list | 18 |
| Suppliers / Packagers: see list | 7 |
| Bulk Api Vendors: see list | 43 |
| Clinical Trials: see list | 193 |
| Patent Applications: see list | 9,931 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see low prices |
| DailyMed Link: | sirolimus at DailyMed |
| Drug Class | mTOR Inhibitor Immunosuppressant Kinase Inhibitor |
| Mechanism of Action | mTOR Inhibitors Protein Kinase Inhibitors |
| Physiological Effect | Decreased Immunologic Activity |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pf Prism Cv | RAPAMUNE | sirolimus | TABLET;ORAL | 021110-003 | Feb 23, 2004 | DISCN | Yes | No | ► Subscribe | ► Subscribe | |||||||||||||||||||
Pf Prism Cv | RAPAMUNE | sirolimus | TABLET;ORAL | 021110-002 | Aug 22, 2002 | AB | RX | Yes | Yes | ► Subscribe | ► Subscribe | ||||||||||||||||||
Dr Reddys Labs Ltd | SIROLIMUS | sirolimus | TABLET;ORAL | 201578-002 | Oct 27, 2014 | AB | RX | No | No | ► Subscribe | ► Subscribe | ||||||||||||||||||
Pf Prism Cv | RAPAMUNE | sirolimus | TABLET;ORAL | 021110-003 | Feb 23, 2004 | DISCN | Yes | No | 5,989,591*PED | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Dr Reddys Labs Ltd | SIROLIMUS | sirolimus | TABLET;ORAL | 201578-001 | Oct 27, 2014 | AB | RX | No | No | ► Subscribe | ► Subscribe | ||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Expired Orange Book Patents
Available with subscription
Paragraph IV Activity
Available with subscription
Patent Maintenance
Available with subscription
Non-Orange Book Patents
Available with subscription
International Patents
Available with subscription
Supplementary Protection Certificates
Available with subscription
To plan ahead for inventory purposes
— Pharmacy purchaser, USA
To monitor patent expirations/loss of exclusivity
— Pharmacy director, USA
To know about pharmaceutical patents and their expiration dates
— Pharmaceutical R&D, Venezuela
To find patent expirations for active pharmaceuticals ingredients
— Drug formulator, Israel
To get upcoming patent expirations for certain drugs
— Journalist, USA
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639
Follow DrugPatentWatch:
